LAD191

Phase 2Small molecule

AAlmirall, S.A.

LAD191 is one of 86 small molecule programs targeting Autoimmune Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune DiseaseActive, not recruiting

Hidradenitis SuppurativaActive, not recruiting

Autoimmune DiseasePhase 1

Active, not recruiting

Hidradenitis SuppurativaPhase 2

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Autoimmune Disease

#DrugCompanyPhaseTrials

Myfortic

Novartis

Phase 3

1 2

Remicade

OOrganon and Co

Phase 3

2 3

Atgam

Novartis

Phase 2

2 4

Cytosar

Teva

Phase 2

1 5

Blincyto

Amgen

Phase 2

1 6

Soliris

Rayos

2 8

Alkeran

AApotex Inc.

Phase 2

1 9

Vepesid

AAvyxa

Phase 2

1 10

Velcade

SShilpa Grover, MD, MPH

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Hidradenitis Suppurativa

NCT07151937

Clinical

Trials by Indication[1]

Hidradenitis Suppurativa1 trial

A Study of LAD191 in Adults With Hidradenitis Suppurativa

Not yet recruiting·AAlmirall, S.A.·Phase 2·NCT07151937·200 enrolled

Autoimmune Disease1 trial

Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease

Completed·AAlmirall, S.A.·Phase 1·NCT06488209·69 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LAD191. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LAD191 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LAD191. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Almirall, S.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAlmirall, S.A.

LAD191

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Hidradenitis Suppurativa1 trial

Autoimmune Disease1 trial

References

Drug Info

Quick Facts

Related News